Get In Touch with Laguna Bio
Please tell us a little bit about yourself and why you'd like to get connected. Laguna Bio + SOSV will follow up with you via email.
Laguna Bio develops microbe-based cancer therapeutics using its QUAIL platform to activate a powerful innate immune response in the body. Built on highly attenuated microbial vectors, QUAIL engages key in vivo immune pathways to drive anti-tumor activity in AML and other high-risk leukemias as well as sarcomas. By stimulating innate T cell populations and enhancing immune recognition, the platform enables robust, durable activation and expansion of endogenous innate T cells. Laguna Bio is entering human clinical trials in 2026.
2 out of 3 patients with solid tumors don’t experience a robust anti-tumor response, even with cutting-edge cancer therapies
T cells can uniquely generate robust and durable cytotoxicity against cancer and nothing produces more (gamma delta) T cells than Laguna Listeria.
Please tell us a little bit about yourself and why you'd like to get connected. Laguna Bio + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.